Filing Flows › Definitive Healthcare (DH) › R&D spending
Definitive Healthcare (DH) R&D spending by quarter
Definitive Healthcare's R&D spending was $6.7M in Q3 2026 (third quarter 2026), -1% from Q2 2026. Over the last 7 quarters it ranged from $6.5M (Q1 2026) to $10.0M (Q4 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $6.7M | -1% | -12% |
| Q2 2026 | $6.8M | +4% | -15% |
| Q1 2026 | $6.5M | -35% | -30% |
| Q4 2025 | $10.0M | +32% | — |
| Q3 2025 | $7.6M | -5% | — |
| Q2 2025 | $8.0M | -14% | — |
| Q1 2025 | $9.3M | — | — |
Q3 2026 at a glance
Definitive Healthcare, Q3 2026: revenue $54.6M (-9% year over year), operating margin -9.1%, net loss $5.4M, operating cash flow $11.4M. The chart follows the revenue to costs, profit and cash.
Questions
What is Definitive Healthcare's R&D spending?
Definitive Healthcare's R&D spending was $6.7M in Q3 2026 (third quarter 2026), -1% from Q2 2026.
How has Definitive Healthcare's R&D spending changed?
Over the last 7 quarters it ranged from $6.5M (Q1 2026) to $10.0M (Q4 2025).